Back to Journals » Cancer Management and Research » Volume 12

Hepatic Arterial Infusion Combined with Systemic Chemotherapy for Patients with Extensive Liver Metastases from Gastric Cancer

Authors Qiang W, Shi H, Wu J, Ji M, Wu C

Received 12 January 2020

Accepted for publication 31 March 2020

Published 29 April 2020 Volume 2020:12 Pages 2911—2916

DOI https://doi.org/10.2147/CMAR.S245697

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Seema Singh


Weiguang Qiang,1 Hongbing Shi,1 Jun Wu,1 Mei Ji,1 Changping Wu1,2

1Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, People’s Republic of China; 2Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, People’s Republic of China

Correspondence: Changping Wu; Weiguang Qiang
Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, People’s Republic of China
Email wcpjjt@163.com; qwgwutongyu@163.com

Purpose: Liver metastases in patients with gastric cancer often indicate poor prognosis. Once liver metastases are extensive, it is difficult to achieve disease control by using systemic chemotherapy alone. The purpose of this study was to evaluate the effect and safety of hepatic arterial infusion (HAI) combined with systemic chemotherapy on extensive liver metastases from gastric cancer.
Patients and Methods: Between 2012 and 2019, 21 patients with extensive liver metastases from gastric cancer (LMGC) were enrolled in our study. Liver metastases were identified as unresectable and a major factor affecting prognosis mainly based on size and number of intrahepatic lesions. All patients received systemic chemotherapy with S-1 and HAI oxaliplatin plus floxuridine (FUDR).
Results: Liver metastases in 16 patients (76.2%) were evaluated as H3. The overall response rate was 76.2% (9.5% complete response). Intrahepatic and extrahepatic median progression-free survival times were 9.5 and 5.2 months, respectively. Median survival time (MST) was 12.3 months. All patients did not have the toxicity of grade 4. Grade 3 toxic effects included bone marrow suppression (14.3%) and diarrhea (9.5%). The other treatment-related toxicities were mild and reversible.
Conclusion: HAI combined with systemic chemotherapy for extensive LMGC seems to be safe and effective, which achieves a high-local response and may contribute to long survival time for patients.

Keywords: gastric cancer, liver metastases, hepatic arterial infusion, systemic chemotherapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]